Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes

Diabetes mellitus is a lifelong chronic condition that requires self-management. Lifestyle modification and adherence to antidiabetes medications are the major determinants of therapeutic success in the management of diabetes. To assess the effects of a pharmaceutical care (PC) model on medication a...

Full description

Saved in:
Bibliographic Details
Published in:Patient preference and adherence 2014-01, Vol.8 (default), p.1185-1194
Main Authors: Chung, Wen Wei, Chua, Siew Siang, Lai, Pauline Siew Mei, Chan, Siew Pheng
Format: Article
Language:English
Subjects:
Blood glucose
Diabetes
Diabetes research
Drug therapy
Glucose
glycemic control
Health aspects
Medical records
medication adherence
Medicine
Original Research
Patient compliance
Patients
pharmaceutical care
Pharmaceuticals
Primary care
Teaching hospitals
Type 2 diabetes
type 2 diabetes mellitus
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetes mellitus is a lifelong chronic condition that requires self-management. Lifestyle modification and adherence to antidiabetes medications are the major determinants of therapeutic success in the management of diabetes. To assess the effects of a pharmaceutical care (PC) model on medication adherence and glycemic levels of people with type 2 diabetes mellitus. A total of 241 people with type 2 diabetes were recruited from a major teaching hospital in Malaysia and allocated at random to the control (n=121) or intervention (n=120) groups. Participants in the intervention group received PC from an experienced pharmacist, whereas those in the control group were provided the standard pharmacy service. Medication adherence was assessed using the Malaysian Medication Adherence Scale, and glycemic levels (glycated hemoglobin values and fasting blood glucose [FBG]) of participants were obtained at baseline and after 4, 8, and 12 months. At baseline, there were no significant differences in demographic data, medication adherence, and glycemic levels between participants in the control and intervention groups. However, statistically significant differences in FBG and glycated hemoglobin values were observed between the control and intervention groups at months 4, 8, and 12 after the provision of PC (median FBG, 9.0 versus 7.2 mmol/L [P
ISSN:1177-889X
1177-889X
DOI:10.2147/PPA.S66619